2024-03-19 08:36:43 ET
DENVER, Colo., Mar 19, 2024 ( 247marketnews.com )- Clearmind Medicine Inc. (NASDAQ: CMND ) stated, this morning, that it received divisional patent approval by the China National Intellectual Property Administration, granting Clearmind a broader claim than a previously announced patent application.
“We are proud to receive once again recognition of our innovative treatment for binge behaviors. We believe that this approval is a major milestone and significantly expands our IP protection as a leader in psychedelic-derived therapeutics,” said Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani. “In various pre-clinical studies, carried out during the past 2 years, MEAI has demonstrated its ability to regulate binge behaviors, addiction and other mental health disorders. We believe these strong results demonstrate the significant potential of the MEAI molecule for various indications.”
For further CMND commentary, please click here .
The post Clearmind Medicine Granted Divisional Patent Approval in China for Psychedelic Treatment appeared first on 24/7 MarketNews .
For further details see:
Clearmind Medicine Granted Divisional Patent Approval in China for Psychedelic Treatment